Article

1 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



Journal of the American Academy of Dermatology
Volume 74, n° 6
pages 1160-1165 (juin 2016)
Doi : 10.1016/j.jaad.2015.10.051
accepted : 25 October 2015
Original Articles

Immunologic prediction of relapse in patients with pemphigus vulgaris (PV) in clinical remission
 

Maryam Daneshpazhooh, MD a, , Vahid Zafarmand Sedigh, MD a, Kamran Balighi, MD a, S. Hamed Hosseini, MD b, Ali Ramezani, MD a, Mohammad-Sadegh Kalantari, MD a, Narges Ghandi, MD a, Maryam Ghiasi, MD a, Azita Nikoo, MD c, Cheyda Chams-Davatchi, MD a
a Autoimmune Bullous Diseases Research Center, Department of Dermatology, Tehran University of Medical Sciences, Tehran, Iran 
b School of Public Health, Tehran University of Medical Sciences, Tehran, Iran 
c Department of Dermatopathology, Tehran University of Medical Sciences, Tehran, Iran 

Reprint requests: Maryam Daneshpazhooh, MD, Autoimmune Bullous Diseases Research Center, Razi Hospital, Vahdate-Eslami Square, 11996 Tehran, Iran.Autoimmune Bullous Diseases Research CenterRazi HospitalVahdate-Eslami SquareTehran11996Iran
Abstract
Background

Pemphigus vulgaris (PV) is characterized by multiple relapses, occurring especially in patients on minimal therapy or off therapy.

Objective

To identify immunologic predictors (anti-desmoglein [Dsg] 1 and 3 antibodies; direct immunofluorescence [DIF]) for relapse in PV patients.

Methods

Eighty-nine patients in complete clinical remission for at least 6 months and receiving less than or equal to 10 mg prednisolone daily and no immunosuppressive drugs were evaluated using DIF (n=89) and Dsg ELISA (n=46). They were followed until relapse or for at least 18 months.

Results

DIF was positive in 44 of 89 patients (49.5%); anti-Dsg 3 antibodies were detected in 18 of 46 patients (39.1%) and anti-Dsg 1 antibodies were detected in 4 of 46 patients (8.7%). Relapse occurred in 38 patients (42.7%). Mean relapse-free time was significantly shorter in anti-Dsg 3-positive patients compared to anti-Dsg 3- negative patients (P = .015) and in DIF-positive patients compared to DIF-negative patients (P = .047), but not in anti-Dsg 1- positive patients compared to anti-Dsg 1-negative patients (P = .501). Sensitivity and predictive values of neither of these tests were high.

Limitations

Small number of anti-Dsg 1-positive patients and use of conventional ELISA.

Conclusion

Positive anti-Dsg 3 ELISA and, to a lesser degree, positive DIF are predictors of relapse in PV patients in clinical remission. Decision on discontinuing treatment should be based on the results of these tests as well as on clinical findings.

The full text of this article is available in PDF format.

Key words : anti-desmoglein 1, anti-desmoglein 3, clinical remission, direct immunofluorescence, pemphigus vulgaris, relapse, relapse-free time

Abbreviations used : CI, DIF, Dsg, ELISA, NPV, PPV, PV



 Funding sources: None.
 Conflicts of interest: None declared.



© 2015  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline
You can move this window by clicking on the headline